SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma board to consider second interim dividend

02 Nov 2015 Evaluate

With reference to the earlier letter dated October 26, 2015, informing that a Meeting of the Board of Directors of the Company will be held on November 06, 2015 to consider, the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2015. Further Aurobindo Pharma has now informed that at the Board Meeting to be held on November 06, 2015, the Board will also consider the proposal of payment of Second Interim Dividend for the year 2015-16.

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1371.90 4.20 (0.31%)
21-Apr-2026 11:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.00
Dr. Reddys Lab 1222.65
Cipla 1229.95
Zydus Lifesciences 931.80
Lupin 2323.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×